Protease Inhibitors (PIs) / Boosted PIs

The Level of Persistent Viremia Below 50 copies/mL Is Associated with Subsequent Rebound to Above 50 HIV RNA copies/mL for Nelfinavir- Treated Subjects, But Not Lopinavir/Ritonavir-Treated Subjects - 7/07/05

Gag Mutations Identified in Wild-type HIV-1 that Impact Viral Replication Capacity (RC) May Represent Cytotoxic T-Lymphocyte (CTL) Escape Mutations 6-27-05

Susceptibility Measurements Using Resistance Test Vectors with or without Patient-Derived C-terminus of RT, RNAseH and Integrase Are Largely Concordant 6-27-05

Determination of Phenotypic Clinical Cutoffs for Atazanavir and Atazanavir/Ritonavir 6-15-05

Reduced Susceptibility to Protease Inhibitors (PI) in the Absence of Primary PI Resistance-Associated Mutations 6-15-05

Return to Conference Main Page